TBCE and psoriasis: As illustrated in Fig. 7(j), treatment with secukinumab suppressed the activation of DCs (labeled with LAMP3) as well as the aberrant differentiation of KCs (labeled with KRT17) in IMQ-induced psoriasis mice.